About us
We are a global leaders in medicinal cannabis, committed to quality, innovation and caring for patients around the world.
Linneo in Figures
- Founded in 2018 and supported by unparalleled heritage and experience in the production of strictly regulated pharmaceutical products spanning more than 90 years.
- First company in Spain with a license for the production and manufacture of medicinal cannabis.
- Present in the main markets of the world with a large-scale expansion plan. Access to more than 8.0 million patients.
- R+D team at the forefront of scientific cannabis knowledge in collaboration with: CDTI, ICEX, Next Generation EU Funds.
- More than 35 million euros of investment in Capex to date.
- 120 employees, of which 65% are women.
- CAGR growth of 150% in the last 3 years.
- GACP Certifications; GLP, GMP 1 and 2.
- 4.7 HA cultivation and processing facilities in Murcia (Spain).
- 8 commercial varieties of dried cannabis flower.
- Committed to minimising the impact of the Company’s operations on the environment and improve sustainability practices – major carbon reduction programme to reduce Linneo Health’s carbon footprint by 60%.
- Dry cannabis flower cultivation capacity in a greenhouse of 8.0 tons, expandable to 17.0 tonnes.
-
Extraction capacity of up to 12,000 tonnes.
through alliances with CMO's.* - Laboratory specialised in cannabis that processes more than 250 analyses per month.
- +30 new varieties in the pipeline.
- 100% private capital.
Leadership
Meet our leadership team
Don Bellamy
Chief Executive Officer
CEO
With a career spanning 30 years, Don has held several positions within the pharmaceutical and regulated cannabis industries prior to becoming CEO at Linneo Health.
Don was previously Senior Vice President for Global Medical Products at Canopy Growth in Canada, where he was responsible for the global strategic and operational development of Spectrum Cannabis and Canopy’s medical prescription business. He also founded the life sciences and medical cannabis consulting firm, Goodfriend Consulting.
Don started his career in the pharmaceutical sector, where he held several positions of increasing responsibility in Baxalta-Shire, Novartis and AstraZeneca. He has extensive experience in global roles, general management, marketing, and business operations. As Global Head of Marketing and Launch Excellence at Baxalta-Shire, he implemented a standardized launch process for the company, estimated to have added $1bn in topline sales.
He brings extensive therapeutical expertise in disease areas such as pain, oncology, and neurological conditions, and has built up an extensive business and regulatory network across the world.
Gerardo Gorostiza
Chief Financial Officer
CFO
Gerardo received degrees in Industrial Engineering in Business Administration and MBA from IE Business School. He has extensive experience in financial management and M&A, having successfully held management positions in various multinational companies (Uralita, Adveo or the Costa Food Group) and started his career as a consultant at PwC. His background supports his position to establish financial health and secure appropriate resources with a vision for future growth for Linneo.
Mª Ángeles Muñoz
Quality & Regulatory
Affairs Director
María Ángeles has more than 20 years of experience in multinationals, small companies (including Novartis, Telstar and Pharmex) and consulting for the pharmaceutical industry, having held various roles related to regulatory strategy and chemical-pharmaceutical documentation at a national and international level. She is greatly knowledgeable about the life cycle of medicines, food supplements, health products and cosmetics, with relevant experience in positions and departments including Director of Consulting, Regulatory Affairs, the departments of Quality, Audits, Validations, Medical Affairs and Pharmacovigilance.
Sergio Moreno
Production
Director
As the Production Director at Linneo Health, Sergio leads a team that ensuring Linneo´s production is in full compliance with GACP and EU-GMP standards. He also oversees Linneo’s search, selection, testing, and licensing of new genetics used in the process. Sergio holds a degree in Agricultural Engineering and has accumulated over 25 years of experience in the industry, working in The Netherlands, Mexico, and Spain.
Sergio is experienced in the successful launch and management of advanced and highly intensive facilities for the manufacturing of high-value products, from agri-food and ornamental to medicinal sectors. At Linneo Health, he has successfully implemented essential infrastructure and facility improvements to enable the cultivation and processing of high-quality products in a safe and efficient environment.
Sergio’s previous roles include COO of Aleia Roses, a sustainable greenhouse operation spanning 14 hectares. For almost 13 years, served as the Director of Technical Operations of Bionatur, the largest hi-tech greenhouse operation in Mexico, covering 85 hectares.
Our history
Linneo Health is a global leader in the research, EU-GMP certified manufacture and supply of medicinal cannabis flowers, extracts and products to pharmaceutical partners developing innovative cannabis-based therapies for patients in need. As the world’s only vertically integrated medicinal cannabis supplier, supported by 90 years of unparalleled heritage and experience in the production of strictly regulated pharmaceutical products, Linneo Health is setting the benchmark for quality in research, cultivation and supply of medicinal cannabis to drive innovation and excellence in the field.
Linneo’s European operations center in Southern Spain is optimally positioned to address the needs of its customers through every stage of product development, regulation and handling. Driven by the belief that people around the world deserve to be treated with cannabis medicine of the highest standard, Linneo’s expertise provides a clear reference for today’s industry, alongside significant expansion capabilities to support the development of tomorrow’s solutions in a rapidly evolving market.
Linneo Health takes 90 years of experience in the agricultural and industrial production of highly regulated narcotics and puts them at the service of the cannabis industry. We work with the highest production standards, and this clear focus on the quality of what we do has been accredited by the EU-GMP and GACP certifications to our production process.
With an ambitious expansion plan, we currently have an installed capacity of 40,000 m2 dedicated to cannabis flowers. In addition, we have an industrial capacity to process more than 12,000 tonnes of plant material per year, destined for the production of extracts and active ingredients derived from cannabis. All this positions us as market leaders and a clear reference in the sector.
